Availability
0
Your Basket is Empty
BT164447

Temozolomide - Bio-X

An imidazotetrazine alkylating agent. Has anti-tumor activity against a broad spectrum of tumors, such as leukemias, lymphomas and solid tumors. Induces G2/M arrest and apoptosis. As a drug resistance-modifying agent it is used for studying drug resistance mechanisms in glioblastoma cell lines.

Technical Data

CAS No: 85622-93-1
Synonyms: 3,4-Dihydro-3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide; NSC 362856; CCRG 81045
Product Code: BT164447
MDL No: MFCD00866492
Chemical Formula: C6H6N6O2
Molecular Weight: 194.15

References


  • Clark AS et al (1995). Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem 38(9):1493-504.
  • Newlands ES et al (1997). Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev 23: 35.
  • Marchesi F et al (2007). Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56(4):275-87.
  • Hait WN and Hambley TW (2009). Targeted cancer therapeutics. Cancer Res 69(4):1263-7.

Solubility

Stability

Further Information


Datasheets


Temozolomide - Bio-X

CAS No:
85622-93-1
Synonyms:
3,4-Dihydro-3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide
NSC 362856
CCRG 81045
MDL No:
MFCD00866492
Chemical Formula:
Molecular Weight:
194.15
Product Structure
References:
1. Clark AS et al (1995). Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem 38(9):1493-504.
2. Newlands ES et al (1997). Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev 23: 35.
3. Marchesi F et al (2007). Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56(4):275-87.
4. Hait WN and Hambley TW (2009). Targeted cancer therapeutics. Cancer Res 69(4):1263-7.

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...